In melanoma, multiple mechanisms of resistance to BRAF and MAP2K1/2 inhibition, including MAPK1/3 reactivation and PI3K-AKT1 pathway activation, converge upon MYC as a key element [143]. The gene discussed is MAP2K1; the disease is melanoma.